Cargando…

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP

AIM: TransCon CNP is a novel prodrug designed to provide sustained release of C‐type natriuretic peptide (CNP) for once‐weekly therapy, addressing the pathology leading to aberrant skeletal development in achondroplasia. This phase 1 trial was initiated to assess the safety, tolerability, pharmacody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Breinholt, Vibeke Miller, Mygind, Per Holse, Christoffersen, Eva Dam, Zhang, Ying, Ota, Sho, Will Charlton, R., Viuff, Dorthe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796269/ https://www.ncbi.nlm.nih.gov/pubmed/35481707 http://dx.doi.org/10.1111/bcp.15369

Ejemplares similares

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency
por: Höybye, Charlotte, et al.
Publicado: (2017)

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
por: Savarirayan, Ravi, et al.
Publicado: (2023)

The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency
por: Sprogøe, Kennett, et al.
Publicado: (2017)

THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
por: Savarirayan, Ravi, et al.
Publicado: (2023)

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
por: Rosen, David B, et al.
Publicado: (2022)

Intratumoral delivery of TransCon(™) TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
por: Zúñiga, Luis Alejandro, et al.
Publicado: (2022)

CNP, the Third Natriuretic Peptide: Its Biology and Significance to the Cardiovascular System
por: Nakagawa, Yasuaki, et al.
Publicado: (2022)

OP Transcon 2018 Compilation
Publicado: (2019)

PP Transcon 2018 Compilation
Publicado: (2019)

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults
por: Karpf, David B, et al.
Publicado: (2020)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

TRANSCON 2022 B: Poster Papers
Publicado: (2023)

TRANSCON 2022 B: Oral Abstracts
Publicado: (2023)

Pivotal vascular homeostatic role for endothelium-derived C-type natriuretic peptide (CNP)
por: Hobbs, Adrian J
Publicado: (2015)

Regulation and Function of C-Type Natriuretic Peptide (CNP) in Gonadotrope-Derived Cell Lines
por: Mirczuk, Samantha M, et al.
Publicado: (2019)

Effect of C-Type Natriuretic Peptide (CNP) on Spermatozoa Maturation in Adult Rat Epididymis
por: Zhao, Hu, et al.
Publicado: (2023)

C-type natriuretic peptide (CNP) in the paraventricular nucleus-mediated renal sympatho-inhibition
por: Zheng, Hong, et al.
Publicado: (2023)

A qualitative study of the impacts of having an infant or young child with achondroplasia on parent well-being
por: Pfeiffer, Kathryn M., et al.
Publicado: (2021)

Functioning and well‐being in older children and adolescents with achondroplasia: A qualitative study
por: Pfeiffer, Kathryn M., et al.
Publicado: (2021)

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

N-Terminal pro C-Type Natriuretic Peptide (NTproCNP) and myocardial function in ageing
por: Keng, Bryan M. H., et al.
Publicado: (2018)

C-Type Natriuretic Peptide (CNP) Could Improve Sperm Motility and Reproductive Function of Asthenozoospermia
por: Li, Na, et al.
Publicado: (2022)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

Assessing the impacts of having a child with achondroplasia on parent well-being
por: Pfeiffer, Kathryn M., et al.
Publicado: (2020)

Correction to: Assessing the impacts of having a child with achondroplasia on parent well-being
por: Pfeiffer, Kathryn M., et al.
Publicado: (2020)

Assessing physical symptoms, daily functioning, and well‐being in children with achondroplasia
por: Pfeiffer, Kathryn M., et al.
Publicado: (2020)

Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
por: Bakker, Charlotte, et al.
Publicado: (2020)

Changes in C-type natriuretic peptide (CNP) levels in the plasma and cerebrospinal fluid of the patients with subarachnoid hemorrhage
por: Ikeda, K, et al.
Publicado: (1999)

Changes in the C-type Natriuretic peptide (CNP) and NO derivatives in the plasma and CSF of the patients with subarachnoid hemorrhage (SAH)
por: Ikeda, K, et al.
Publicado: (2000)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

38(th) ISBTI Annual Conference, TRANSCON 2013, Surat
Publicado: (2014)

C-Type Natriuretic Peptide (CNP) Inhibition of Interferon-γ-Mediated Gene Expression in Human Endothelial Cells In Vitro
por: Day, Amy, et al.
Publicado: (2018)

OR29-5 Phase 3 PaTHway Trial: Participants Treated With TransCon PTH Achieved Independence From Conventional Therapy While Maintaining Normal Serum Calcium
por: Khan, Aliya
Publicado: (2022)

39(th) ISBTI Annual Conference, TRANSCON 2014, Surat Patiala
Publicado: (2015)

40(th) ISBTI Annual Conference, TRANSCON 2015, New Delhi
Publicado: (2016)

Mutation of three amino acids in the disulfide-ring of a CNP based chimeric natriuretic peptide alters its vascular properties
por: Chen, Horng H, et al.
Publicado: (2009)

Comparative measurement of CNP and NT-proCNP in human blood samples: a methodological evaluation
por: Kuehnl, Andreas, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ono124s6sc3d86jdco78qocktg